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ABSTRACT:  34 
Beta-alanine (BA) supplementation increases muscle carnosine content (MCarn), and is ergogenic in many situations. Currently, many questions on the 35 
nature of the Mcarn response to supplementation are open, and the response to these has considerable potential to enhance the efficacy and applications 36 
of this supplementation strategy. Objective: To conduct a Bayesian analysis of available data on the Mcarn response to BA supplementation. Methods: A 37 
systematic review with meta-analysis of individual and published aggregate data using a dose response (Emax) model was conducted. The protocol was 38 
designed according to PRISMA guidelines. A three-step screening strategy was undertaken to identify studies that measured the Mcarn response to BA 39 
supplementation. In addition, individual data from 5 separate studies conducted in the authors’ laboratory were analysed. Data were extracted from all 40 
controlled and uncontrolled supplementation studies conducted on healthy humans. Meta-regression was used to consider the influence of potential 41 
moderators (including dose, sex, age, baseline Mcarn and analysis method used) on the primary outcome. Results and Conclusion: The Emax model 42 
indicated that human skeletal muscle has large capacity for non-linear Mcarn accumulation, and that commonly used BA supplementation protocols may 43 
not come close to saturating muscle carnosine content. Neither baseline values, nor sex, appear to influence subsequent response to supplementation. 44 
Analysis of individual data indicated that Mcarn is relatively stable in the absence of intervention, and effectually all participants respond to BA 45 
supplementation (99.3% response [95%CrI: 96.2 – 100]).  46 
 47 
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INTRODUCTION 68 
Carnosine is a dipeptide formed from the amino acids β-alanine and L-histidine, and is present in high concentrations in human skeletal muscle 69 
(approximately 20 - 30 mmol·kg-1 dry muscle). Its purported roles include: proton buffering [1]; anti-oxidation [2]; anti-glycation; metal chelation [3] and 70 
influencing calcium sensitivity [4,5], and hence muscle contractility. Although in vitro evidence supports carnosine’s capacity to contribute to each of these 71 
processes, the strongest line of in vivo and in vitro evidence supports an important role for carnosine in intracellular skeletal muscle buffering [3,6]. The 72 
pKa of carnosine’s imidazole ring (6.83 [7]) renders it ideally placed to aid in pH regulation within the physiological range of skeletal muscle (which 73 
decreases from approximately 7.1 at rest to 6.5 after exhaustive exercise [8]). This mechanistic action is particularly relevant in a sporting context, given 74 
that sustained high-intensity efforts are largely fuelled by anaerobic bioenergetic pathways, which lead to hydrogen ion accumulation and an acidic 75 
environment. Acidosis is known to contribute to fatigue and limit performance via a wide range of mechanisms [9]. As such, the presence of intracellular 76 
pH buffers such as carnosine are essential to maintain high intensity muscle contraction, and hence to sustain performance.   77 
 78 
Given the importance of carnosine to athletic performance, considerable research efforts have been made to investigate both means to increase it, and 79 
in what situations such increases are ergogenic.  In 2006, Harris and colleagues [10] published a series of studies indicating that β-alanine (BA) availability 80 
was the limiting factor in intramuscular carnosine synthesis, and that supplementation with this amino acid could substantially increase muscle carnosine 81 
content (MCarn). Shortly after, the same group reported that BA supplementation (mean of 5.2 g·day-1 for 4 weeks) was ergogenic to high-intensity exercise 82 
performance [11]. Since then, the ergogenic benefits of this supplementation strategy have been tested and proven in a wide range of models and recently, 83 
our group published a meta-analysis showing that BA supplementation is most ergogenic in capacity-based exercise tests that last between 30 seconds 84 
and 10 minutes [12]. This strong evidence supporting the ergogenic potential of BA supplementation has earned it its place as one of the world’s most 85 
popular sports supplements, and it is one of just five ergogenic supplements endorsed by the International Olympic Committee [13].  86 
 87 
It seems that substantial amounts of BA are required to increase MCarn content, with most studies using doses of approximately 3.2 – 6.4 g·day-1, for 88 
periods ranging from 4 – 24 weeks. But many questions about the nature of the muscle carnosine response to BA supplementation remain open, and 89 
substantial research efforts are being made to refine BA dosing strategies in order to optimize its efficacy and applicability [14]. For example, inter-90 
individual variation in response to supplementation is high [12], yet little is known about what factors underpin this [15]. What is the capacity of the muscle 91 
to uptake BA and increase MCarn? What is the individual proportion of response to BA supplementation, and do baseline levels dictate the extent of this? 92 
Do sex or age influence response to supplementation? To address these questions, we employed a comprehensive analysis that included individual 93 
participant data from multiple studies conducted within our laboratory; and combined these findings with summary published data using a frequently 94 
used dose-response model (Emax). 95 
  96 
METHODS 97 
The protocol for this study was designed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The 98 
Population, Intervention, Comparator, Outcomes and Study Design (PICOS) approach was used to guide the inclusion and exclusion of studies for this 99 
review and are described in Table 1.  100 
 101 
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Table 1: Study Inclusion and Exclusion Criteria  102 
Population: Healthy individuals of any age or physical activity level. 
Intervention: Original studies investigating the effects of oral BA supplementation on skeletal 
MCarn content. 
Comparator: No human comparators were required in the studies included in this review, 
although the data from placebo groups were used to quantify biological variability 
across the times periods investigated, when available. 
Outcomes:  The primary outcome was the effect of BA supplementation on skeletal MCarn 
concentration. Potential moderators to this response included dose, sex, age, 
baseline MCarn and the method used to measure MCarn. 
Study Design: Controlled or uncontrolled intervention studies.  
 103 
Search Strategy 104 
The search strategy was based on a three-step screening (title/abstract screening, full-text screen and full text appraisal), independently undertaken by 105 
two reviewers. This search was originally conducted to inform a systematic risk assessment on the use of BA supplementation [16]. This risk assessment 106 
included all BA supplementation studies (including both human and animal models). One hundred and one human studies were included in that 107 
investigation, and were subsequently screened to identify those that included a MCarn measurement. The search strategy, including databases and 108 
keywords used has been described in detail elsewhere [16] and the protocol for that review was prospectively registered ((PROSPERO registration no. 109 
CRD42017071843). 110 
 111 
Data Analysis 112 
The present study comprised both individual and aggregate data meta-analyses from a Bayesian perspective. Individual data were pooled using Bayesian 113 
mixed effects multilevel models. Analyses were performed on the outcome variable MCarn (absolute value) to quantify the effects of beta-alanine 114 
supplementation and random noise due to biological variation and measurement error. Additionally, proportion of response was estimated across 115 
controlled studies by calculating interindividual difference in response to supplementation and comparing this to a non-zero increase in MCarn [17]. 116 
Bayesian estimates of the standard deviation in observed change from active and placebo groups were used to obtain the intervention response standard 117 
deviation (?̂?𝐼𝑅) describing interindividual difference in response. Aggregate data meta-analyses were performed using published pre- and post-intervention 118 
mean and standard deviation values. Values were transformed into standardized mean differences (SMD) and sampling variance calculated using methods 119 
described previously [18]. Three-level mixed effects models were used to quantify the effects of supplementation dose. Insufficient data were available to 120 
allow investigation of the interaction between daily dose and intervention duration and so the total cumulative dose ingested was selected as the primary 121 
outcome, which previous research has identified as being more influential than either daily dose or intervention duration [16,19,20]. Subset analyses using 122 
study covariates were used to assess the effects of sex, age or measurement method on the main effect of BA supplementation. Finally, a model-based 123 
approach was employed to investigate the dose-response relationship between cumulative BA supplementation and the SMD. A standard four parameter 124 
sigmoid predicted maximum effect (Emax) model was estimated with: 125 
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𝐸 = 𝐸0 +
𝐸𝑚𝑎𝑥 × 𝐶
𝛾
𝐸𝐶50
𝛾 + 𝐶𝛾
 126 
Where 𝐸 is the effect size (SMD), 𝐸0 is the baseline effect, 𝐸𝑚𝑎𝑥 is the maximum effect, 𝐸𝐶50 is the cumulative dose that provides 50% of the maximum 127 
effect, 𝐶  is the input (cumulative dose) and 𝛾  is the Hill coefficient controlling the slope of the sigmoid response. Inferences from all models were 128 
performed on posterior samples generated by Markov Chain Monte Carlo with Bayesian 95% credible intervals (CrIs) constructed to enable probabilistic 129 
interpretations of parameter values. Models were run in OpenBUGS (version 3.2.3, MRC Biostatistics Unit) and in R (version 3.3.1 R Development Core 130 
Team) using the R2OpenBugs package. 131 
 132 
RESULTS:  133 
Study characteristics 134 
Twenty-five studies were identified in the systematic search and included in the meta-analysis [10–12,19–40], along with three, currently unpublished, 135 
data sets from the authors’ lab (see Figure 1 for search flow diagram). In total, 575 participants (comprising 486 men and 89 women) were included, of 136 
which 382 consumed BA, with the remaining 193 allocated to a placebo intervention. The majority of studies were conducted on healthy young adults 137 
(mean age (yrs) = 23.89, SD = 5.46), with only one study conducted on elderly (mean age (yrs) = 64.34, SD = 4.99, [26]). An overview of all included studies 138 
is presented in Supplementary File 1. Analyses were completed on subsets of the data depending on the specific analysis and suitability of each study set, 139 
as described below.  140 
 141 
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 142 
Figure 1: Search Flow Diagram 143 
 144 
Individual Data:  145 
Complete individual data sets were obtained from five studies conducted within the authors laboratory. Two of these studies were identified in the 146 
systematic search [12,22], while the remaining three are currently unpublished. Ninety-nine participants were available (BAn = 67, PLAn = 32) comprising a 147 
total of 232 observations. All studies provided a BA dose of 6.4 g·day-1 with observations ranging from 4 to 24 weeks post baseline. BA supplementation 148 
increased MCarn on average by 16.0 mmol·kgDM-1 ([95%CrI: 12.4 – 19.6] compared to placebo. Regression analyses with duration centred at 4 weeks were 149 
completed to determine if the effects of supplementation increased beyond this point (BAn = 50, 134 total observations). The mean change in MCarn at 4 150 
weeks was 14.0 mmol·kgDM-1 [95%CrI: 10.1 – 18.1], with a positive regression slope indicating a further 0.5 [95%CrI: 0.2 – 0.7] mmol·kgDM-1 increase per 151 
week. Analyses of the same data also demonstrated that baseline levels of MCarn were not associated with changes due to supplementation (-0.1 [95%CrI: 152 
-0.3 – 0.1]). The amount of random noise in MCarn values due to biological variation and measurement error (i.e., typical variation) was estimated using 153 
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observations from placebo groups. The standard deviation of residuals from the multilevel model representing typical variation was 4.1 mmol·kgDM-1 154 
([95%CrI: 3.4-5.1], PLAn = 18, 61 total observations). Calculation of proportion of response first required an estimate of the intervention response standard 155 
deviation (?̂?𝐼𝑅), which determines the variability of individual change centered on the group pre to post change. The intervention response standard 156 
deviation (?̂?𝐼𝑅) was estimated as 6.6 mmol
.kgDM-1 [95%CrI: 3.4 – 9.4] and the proportion of response was 99.3% [95%CrI: 96.2 - 100].  157 
  158 
Aggregate Data:  159 
Aggregate analyses were based on effect sizes calculated from all available studies using the SMD pre to post change in MCarn levels. One hundred and 160 
eight effect sizes were available from BA groups only, 6 of which were removed as they were outliers (ES > 5).  The multilevel meta-analysis with no study 161 
covariates estimated a large pooled effect size of 1.5 [95%CrI 1.2 – 1.8], with substantial between (𝜏20.5 = 0.6) and within (𝜖20.5 = 0.7) study variance (Figure 162 
2). The same model applied to effect sizes calculated with supplementation and control group data (22 studies and 56 effect sizes) also produced a large 163 
pooled effect size of 1.7 [95%CrI: 1.3 – 2.1], with substantial between (𝜏20.5 = 0.8) and within (𝜖20.5 = 0.5) study variance (Figure 3).  Using a simple linear 164 
model, the effects of cumulative BA dose was assessed by centering on the mean value (208g). Results demonstrated a large effect at the mean cumulative 165 
dose (1.5 [95%CrI: 1.2 – 1.8]) and an estimated 0.23 [95%CrI: 0.06 – 0.49] increase in effect size per additional 100g. Similar results were obtained for 166 
effect sizes calculated with supplementation and control group data (effect at mean: 1.7 [95%CrI: 1.3 – 2.1]; effect per additional 100g: 0.16 [95%CrI: 0.01 167 
– 0.31]). Insufficient data were available to ascertain if age altered the effects of BA supplementation, but subset analyses were conducted to investigate 168 
the impact of sex and the method used to measure MCarn, using effect sizes generated from supplementation groups only. Sixteen studies were selected 169 
that used the most common dosing protocol (cumulative dose between 130 and 180g) comprising a total of 56 effect sizes. For the sex comparison there 170 
were 8 effect sizes from a female only group, 38 effect sizes from a male only group and 10 effect sizes from a mixed group. No substantive evidence of a 171 
gender effect was obtained (male vs female: -0.32 [95%CrI:-1.1 – 0.43]; male vs mixed: -0.00 [95%CrI: -0.95 – 0.88]). Across the 16 studies, 40 effect sizes 172 
were obtained from MCarn values measured with non-invasive scanning devices (i.e., HR-MRS) and 16 effect sizes obtained with muscle biopsy based 173 
analyses (mainly assessed by HPLC, with one study using UPLC and one using mass spectrometry), with some evidence of increased effects with HPLC (0.16 174 
[95%CrI: 0.01 – 0.43]). 175 
 176 
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 177 
Figure 2: Bayesian Forest Plot of multilevel meta-analysis with non-controlled effect sizes 178 
 179 
 180 
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 181 
Figure 3: Bayesian Forest Plot of multilevel meta-analysis with controlled effect sizes 182 
 183 
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Emax Model 184 
The predicted maximum effect of BA supplementation (Emax) was 3.0 (50%CrI 2.2 – 3.7) and the estimated total cumulative dose (g) required to achieve 185 
50% of this maximum effect (ED50) was 377g (50%CrI 210 – 494). A density plot with the Emax curve generated from median parameter values is provided 186 
in Figure 4. An extrapolation of posterior samples from the Emax model was performed to estimate probabilities that percentage of maximum effect could 187 
be achieved with cumulative doses ranging from 1000 to 1500g (see Table 2). These results estimated, for example, that the probability of obtaining at 188 
least 70% of maximum effect with a cumulative dose of 1000g was 0.68.   189 
 190 
 191 
Figure 4: Density plot of Bayesian Emax model predicting effect of cumulative BA supplementation on muscle carnosine content. Note: Darker areas 192 
represent more common Emax trajectories. White triangles represent Emax generated with median parameter values.  193 
 194 
Table 2: Probability table representing the chance that various cumulative doses (columns) create a response greater than the specified percentage of 195 
EMax (rows) based on Bayesian model generated. 196 
Percentage of EMax 1000g 1100g 1200g 1300g 1400g 1500g 
70% 0.68 0.73 0.77 0.80 0.83 0.85 
80% 0.45 0.48 0.51 0.54 0.56 0.59 
90% 0.31 0.33 0.35 0.37 0.38 0.40 
Values in table represent probabilities (p) 0 ≤ p ≤ 1. 197 
 198 
 199 
 200 
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Discussion:  201 
The purpose of this study was to conduct a comprehensive analysis with various modelling techniques to synthesize existing knowledge about the MCarn 202 
response to BA supplementation. Collectively, our findings and models employed indicated that human skeletal muscle has large capacity for MCarn 203 
accumulation, and that commonly used protocols (e.g., 4 weeks at 6.4 g·day-1) may not come close to saturating muscle carnosine content. Baseline values 204 
do not appear to influence subsequent response to supplementation and the non-linear response to supplementation was not influenced by sex. Analysis 205 
of individual data indicated that muscle carnosine content is relatively stable in the absence of the intervention, and that effectually all (99.3% [95%CrI: 206 
96.2 – 100]) participants respond to BA supplementation.  207 
 208 
Our observation that humans have large capacity for non-linear MCarn accumulation align with a recent theoretical model proposed by Spelnikov & Harris 209 
[41]. Their model describes changes in MCarn over time with BA supplementation, and was based on three studies that used a slow release BA formulation. 210 
The authors described absolute increases in MCarn as a product of the rates of synthesis and decay, with carnosine synthesis considered to be constant in 211 
relation to time and first order to daily BA dose. Similarly, carnosine decay was also considered to be first order, but in relation to total MCarn content. As 212 
such, carnosine decay increases when absolute content is higher and so the rate of MCarn accumulation due to BA induced elevations in synthesis will 213 
slow. Tissue saturation represents the point at which the rates of synthesis match decay, and so content will remain constant despite continued 214 
supplementation. The lack of data at higher BA doses limits precision regarding the point at which human skeletal muscle saturation may occur; however, 215 
our analyses suggest that humans have very large capacity to accumulate MCarn and that naturally occurring baseline levels are far below that which the 216 
muscle is capable of maintaining. 217 
 218 
Our analyses indicate that the nature of individual MCarn response to BA supplementation differs from other commonly used supplements, such as 219 
creatine. Human skeletal muscle appears to reach creatine saturation at approximately 140 – 160 mmol.kgDM-1 [42] and this can be achieved within 5 days 220 
of high-dose supplementation. Response to creatine supplementation is largest in those with lowest baseline levels, whereas individuals whose creatine 221 
content is habitually closer to this saturation point gain smaller benefit from supplementation [42]. In contrast, we observed no evidence of an influence 222 
of baseline carnosine content on the subsequent response to supplementation. This makes sense when considered in relation to our predictive model, as 223 
it appears that we have very large capacity to accumulate MCarn – far greater than is achieved with commonly used protocols (e.g., 179.2 grams provided 224 
as 6.4g·day-1 for 4 weeks). This may be because baseline MCarn contents (approximately 25 mmol·kgDM-1) are substantially lower than those observed for 225 
creatine, with many individuals having baseline contents close to the proposed creatine saturation limit of 140 – 160 mmol·kgDM-1. These data, in turn, 226 
raise another interesting question. Does human skeletal muscle have a largely uniform saturation point, after which no further increases can be attained 227 
(as seems to be the case with creatine)? Or does capacity to accumulate MCarn vary widely between individuals, with each having their own upper limit? 228 
Currently, insufficient data using very high BA protocols on MCarn precludes the answering of this question, but one thing that is clear is that human 229 
skeletal muscle has large capacity to uptake BA and to increase MCarn above naturally occurring, non-supplemented levels.    230 
 231 
Our data indicated that humans have large capacity for MCarn accumulation, and this, in turn, raises other important questions, e.g., is maximal MCarn 232 
accumulation necessary, or even desirable? Theoretically, the greater the increase in MCarn content, the greater its ability to buffer, and to contribute to 233 
other processes, and so intuitively, attaining the largest increases possible seems desirable. Two studies did report that larger MCarn increases were 234 
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associated with greater performance effects [11,12], but meta-analytic data does not support this, and the total dose ingested was previously reported 235 
not to influence the effect on exercise performance [18]. It would be counterintuitive to believe that performance benefits would continue to linearly 236 
increase with ever-increasing MCarn, given that numerous factors, apart from acidosis, contribute to fatigue [43], and so it makes sense that at some 237 
point, performance benefits would plateau. Numerous studies have reported that approximately 179g of BA can be ergogenic, and so it seems MCarn 238 
saturation is not essential for BA supplementation to be ergogenic, although it does remain to be seen whether greater increases can elicit greater effects 239 
on exercise performance. A very important avenue for future research is the identification of the lowest MCarn increase necessary to elicit an ergogenic 240 
effect, along with the point after which no further benefits can be obtained. This information could have large potential to enhance the applicability and 241 
efficacy of BA supplementation strategies. For example, it seems that the largest gains in MCarn are attained in the earlier phases of supplementation (see 242 
Figure 4). It would be of interest to identify if strategies such as meal co-ingestion [33],intake in proximity to training [39] or intake in slow-release capsules 243 
[35] can influence the early response to supplementation [14] and whether this, in turn, meaningfully impacts exercise performance.  244 
 245 
The current analysis also brought to light some interesting points about the nature of carnosine response to supplementation, which has implications for 246 
future study design. It seems that in the absence of intervention carnosine is relatively stable in the muscle, likely due to low intramuscular carnosinase 247 
and roughly equivalent synthesis and degradation rates [3]. Our analysis of individual data indicated typical variation of approximately 4 mmol.kgDM-1 248 
across a 4-week period. Previously, two muscle samples taken from the same biopsy cut showed a variation of approximately 1mmol.kgDM-1 [44], and so 249 
measurement error likely accounts for at least a quarter of this variation (and potentially more). It was interesting to observe that both within and between 250 
study variance were large and similar. A large proportion of this sampling error is likely due to small sample sizes. Typically the use of a control group 251 
would be recommended to normalize the effects of the intervention against those of usual biological variability [17]. But in this situation we observed little 252 
variation in placebo group MCarn, while the effects of intervention studies when analysed both with and without controlling for the effects of the placebo 253 
group were similar (ES (95%CrI): 1.7 (1.3 – 2.1) versus 1.5 (1.2 – 1.8). This implies that the control group adds little value to the analysis, likely because of 254 
MCarn stability and the large effect of supplementation. In future investigations of the MCarn response to BA in young healthy males (and particularly 255 
those for which resources are limited) it may be prudent to direct resources toward the intervention group, in order to reduce within study variance. It is 256 
important to note that this recommendation applies only to studies on the MCarn response to BA supplementation. The influence of BA supplementation 257 
on exercise performance is far less well-characterized and subject to substantially more sources of internal and external variability and so control groups 258 
are essential in studies for which exercise is the primary outcome of interest.  259 
 260 
In addition to characterizing the nature of MCarn response to BA supplementation, we also considered the influence of various potential moderators on 261 
this response. In relation to the method of assessment, it seems that lower effect estimates are generally observed when MCarn is measured using the 262 
HR-MRS technique when compared to those obtained using HPLC analysis of muscle biopsies. When considering the influence of non-modifiable factors 263 
on the MCarn response to supplementation (namely age and sex), we were unable to conduct analyses on the influence of age, as most studies were 264 
conducted in young men, and insufficient data in older and younger groups was available. Women have previously been reported to have lower MCarn 265 
than men [45,46], but our data indicate that both men and women have a similar response to BA supplementation. This implies that the lower values 266 
previously reported in women are unlikely to relate to an inherent gender dysmorphism in the biological factors that underpin carnosine metabolism.  267 
 268 
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In conclusion, our findings indicate that human skeletal muscle has large capacity to accumulate carnosine. MCarn remains stable in the absence of 269 
intervention and neither low baseline MCarn levels, nor sex, influence the subsequent response to BA supplementation. In turn, these findings lead to 270 
other questions, the response to which may have large implications for future practice. From the point of view of athletic performance, key questions 271 
include: what is the absolute MCarn increase required to elicit an ergogenic effect, along with the point after which no further benefits are attained? It is 272 
clear that 4 weeks of BA supplementation can be ergogenic, but can this be achieved earlier? Can strategies to enhance the early response to BA 273 
supplementation meaningfully impact the subsequent ergogenic benefits? The response to these questions may progress practical application of this 274 
supplementation strategy, with potential benefit to many athletic and clinical populations.  275 
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